Logo image of TH.CA

THERATECHNOLOGIES INC (TH.CA) Stock Fundamental Analysis

TSX:TH - CA88338H7040 - Common Stock

4.45 CAD
-0.02 (-0.45%)
Last: 8/29/2025, 7:00:00 PM
Fundamental Rating

3

Overall TH gets a fundamental rating of 3 out of 10. We evaluated TH against 24 industry peers in the Biotechnology industry. TH has a medium profitability rating, but doesn't score so well on its financial health evaluation. TH has a valuation in line with the averages, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year TH has reported negative net income.
In the past year TH had a positive cash flow from operations.
TH had negative earnings in each of the past 5 years.
TH had negative operating cash flow in 4 of the past 5 years.
TH.CA Yearly Net Income VS EBIT VS OCF VS FCFTH.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M -40M

1.2 Ratios

TH has a better Return On Assets (-17.86%) than 79.17% of its industry peers.
TH has a better Return On Invested Capital (50.47%) than 100.00% of its industry peers.
Industry RankSector Rank
ROA -17.86%
ROE N/A
ROIC 50.47%
ROA(3y)-32.34%
ROA(5y)-29.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TH.CA Yearly ROA, ROE, ROICTH.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400 -600

1.3 Margins

TH has a Operating Margin of 10.05%. This is amongst the best in the industry. TH outperforms 95.83% of its industry peers.
TH has a Gross Margin of 77.72%. This is amongst the best in the industry. TH outperforms 95.83% of its industry peers.
TH's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 10.05%
PM (TTM) N/A
GM 77.72%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.54%
GM growth 5Y5.34%
TH.CA Yearly Profit, Operating, Gross MarginsTH.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

2

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so TH is creating value.
TH has about the same amout of shares outstanding than it did 1 year ago.
The number of shares outstanding for TH has been reduced compared to 5 years ago.
The debt/assets ratio for TH is higher compared to a year ago.
TH.CA Yearly Shares OutstandingTH.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
TH.CA Yearly Total Debt VS Total AssetsTH.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

TH has an Altman-Z score of -8.33. This is a bad value and indicates that TH is not financially healthy and even has some risk of bankruptcy.
With a decent Altman-Z score value of -8.33, TH is doing good in the industry, outperforming 62.50% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -8.33
ROIC/WACC4.63
WACC10.89%
TH.CA Yearly LT Debt VS Equity VS FCFTH.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

TH has a Current Ratio of 0.84. This is a bad value and indicates that TH is not financially healthy enough and could expect problems in meeting its short term obligations.
TH has a Current ratio (0.84) which is in line with its industry peers.
TH has a Quick Ratio of 0.84. This is a bad value and indicates that TH is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.65, TH is in line with its industry, outperforming 45.83% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.84
Quick Ratio 0.65
TH.CA Yearly Current Assets VS Current LiabilitesTH.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

3

3. Growth

3.1 Past

TH shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by 0.00%.
Looking at the last year, TH shows a small growth in Revenue. The Revenue has grown by 2.19% in the last year.
TH shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.31% yearly.
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-550%
Revenue 1Y (TTM)2.19%
Revenue growth 3Y7.14%
Revenue growth 5Y6.31%
Sales Q2Q%-19.48%

3.2 Future

TH is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 29.71% yearly.
Based on estimates for the next years, TH will show a small growth in Revenue. The Revenue will grow by 6.64% on average per year.
EPS Next Y88.56%
EPS Next 2Y66.79%
EPS Next 3Y46.8%
EPS Next 5Y29.71%
Revenue Next Year-3.03%
Revenue Next 2Y5.03%
Revenue Next 3Y5.76%
Revenue Next 5Y6.64%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
TH.CA Yearly Revenue VS EstimatesTH.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 50M 100M 150M
TH.CA Yearly EPS VS EstimatesTH.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 -1 2 3

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TH. In the last year negative earnings were reported.
A Price/Forward Earnings ratio of 22.99 indicates a rather expensive valuation of TH.
Compared to the rest of the industry, the Price/Forward Earnings ratio of TH indicates a rather cheap valuation: TH is cheaper than 87.50% of the companies listed in the same industry.
TH's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 22.76.
Industry RankSector Rank
PE N/A
Fwd PE 22.99
TH.CA Price Earnings VS Forward Price EarningsTH.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

91.67% of the companies in the same industry are more expensive than TH, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 17.5
TH.CA Per share dataTH.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as TH's earnings are expected to grow with 46.80% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y66.79%
EPS Next 3Y46.8%

More info and screens

0

5. Dividend

5.1 Amount

TH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

THERATECHNOLOGIES INC

TSX:TH (8/29/2025, 7:00:00 PM)

4.45

-0.02 (-0.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-09 2025-07-09/bmo
Earnings (Next)10-08 2025-10-08/bmo
Inst Owners24.06%
Inst Owner ChangeN/A
Ins Owners0.91%
Ins Owner ChangeN/A
Market Cap204.61M
Analysts84
Price Target5.64 (26.74%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-291.26%
Min EPS beat(2)-482.52%
Max EPS beat(2)-100%
EPS beat(4)1
Avg EPS beat(4)-224.76%
Min EPS beat(4)-482.52%
Max EPS beat(4)94.17%
EPS beat(8)5
Avg EPS beat(8)-62.95%
EPS beat(12)6
Avg EPS beat(12)-46.18%
EPS beat(16)6
Avg EPS beat(16)-49.02%
Revenue beat(2)0
Avg Revenue beat(2)-5.7%
Min Revenue beat(2)-9.5%
Max Revenue beat(2)-1.91%
Revenue beat(4)1
Avg Revenue beat(4)-3.24%
Min Revenue beat(4)-9.5%
Max Revenue beat(4)6.97%
Revenue beat(8)1
Avg Revenue beat(8)-5.3%
Revenue beat(12)1
Avg Revenue beat(12)-6.15%
Revenue beat(16)1
Avg Revenue beat(16)-7.55%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-62.5%
EPS NY rev (1m)-124%
EPS NY rev (3m)-124%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.63%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.08%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 22.99
P/S 1.76
P/FCF N/A
P/OCF 21.15
P/B N/A
P/tB N/A
EV/EBITDA 17.5
EPS(TTM)-0.26
EYN/A
EPS(NY)0.19
Fwd EY4.35%
FCF(TTM)-0.09
FCFYN/A
OCF(TTM)0.21
OCFY4.73%
SpS2.52
BVpS-0.84
TBVpS-1.34
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -17.86%
ROE N/A
ROCE 70.09%
ROIC 50.47%
ROICexc 280.14%
ROICexgc N/A
OM 10.05%
PM (TTM) N/A
GM 77.72%
FCFM N/A
ROA(3y)-32.34%
ROA(5y)-29.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.54%
GM growth 5Y5.34%
F-Score4
Asset Turnover1.65
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA 3.84
Cap/Depr 519.63%
Cap/Sales 11.98%
Interest Coverage 1.21
Cash Conversion 67.47%
Profit Quality N/A
Current Ratio 0.84
Quick Ratio 0.65
Altman-Z -8.33
F-Score4
WACC10.89%
ROIC/WACC4.63
Cap/Depr(3y)39.02%
Cap/Depr(5y)23.86%
Cap/Sales(3y)1.73%
Cap/Sales(5y)1.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-550%
EPS Next Y88.56%
EPS Next 2Y66.79%
EPS Next 3Y46.8%
EPS Next 5Y29.71%
Revenue 1Y (TTM)2.19%
Revenue growth 3Y7.14%
Revenue growth 5Y6.31%
Sales Q2Q%-19.48%
Revenue Next Year-3.03%
Revenue Next 2Y5.03%
Revenue Next 3Y5.76%
Revenue Next 5Y6.64%
EBIT growth 1Y125.23%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year4.1%
EBIT Next 3Y43.2%
EBIT Next 5Y34.29%
FCF growth 1Y82.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y143.06%
OCF growth 3YN/A
OCF growth 5YN/A